beatandraise : SEC Filings Research with AI

beta

BRISTOL MYERS SQUIBB CO

Exhibits

d10k.htm dex3b.htm dex10aa.htm dex10cc.htm dex10dd.htm dex10ee.htm dex10mm.htm dex12.htm dex21.htm dex23.htm dex31a.htm dex31b.htm dex32a.htm dex32b.htm bmy-20101231.xml R19.xml R143.xml R131.xml R44.xml R154.xml R80.xml R97.xml R35.xml R106.xml R146.xml R153.xml R120.xml R112.xml R51.xml R116.xml R29.xml R11.xml R10.xml R158.xml R109.xml R60.xml R30.xml R100.xml R139.xml R54.xml R8.xml R36.xml R41.xml R79.xml R66.xml R72.xml R58.xml R156.xml R22.xml R150.xml R89.xml R74.xml R31.xml R45.xml R133.xml R138.xml R43.xml R73.xml R124.xml R49.xml R105.xml R147.xml R53.xml R92.xml R18.xml R107.xml R86.xml R98.xml R123.xml R94.xml R151.xml R32.xml R108.xml R82.xml R67.xml R57.xml R12.xml R3.xml R113.xml R142.xml R134.xml R14.xml R125.xml R90.xml R48.xml R78.xml R15.xml R24.xml R148.xml R69.xml R119.xml R20.xml R136.xml R4.xml R114.xml R83.xml R77.xml R27.xml R101.xml R39.xml R127.xml R75.xml R128.xml R81.xml R96.xml R68.xml R118.xml R135.xml R70.xml R50.xml R33.xml R16.xml R28.xml R102.xml R76.xml R52.xml R62.xml R122.xml R130.xml R9.xml R6.xml R61.xml R88.xml R152.xml R91.xml R85.xml R5.xml R23.xml R115.xml defnref.xml R95.xml R84.xml R155.xml R121.xml R46.xml R21.xml R99.xml R87.xml R13.xml R34.xml R26.xml R93.xml R59.xml R129.xml R64.xml R1.xml R2.xml R132.xml R103.xml R37.xml R63.xml R56.xml R144.xml R111.xml Financial_Report.xls R110.xml R55.xml R157.xml R47.xml R141.xml R38.xml R145.xml R25.xml R7.xml R117.xml R65.xml R137.xml R126.xml R149.xml R40.xml R71.xml R42.xml R17.xml R140.xml R104.xml

Graphics

g129099g91z29.gif

Notes Support

about terms

beatandraise.com

beta

BRISTOL MYERS SQUIBB CO

Statements

Exhibits

Graphics

g129099g91z29.gif

Notes Support

about terms

2.2.0.25falsefalse30503 - Disclosure - ACQUISITIONS (Tables)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010 USD ($) USD ($) / shares $Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Divide< MeasureSchema>http://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_BusinessAcquisitionEntityAcquired AndReasonForAcquisitionAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalseACQUISITIONS3false0bmy_PurchasePriceAllocationTextBlockbmyfalsenadurationPurchase Price Allocation [Text Block]falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00<div> <div class="MetaData"> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="87%"> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Dollars in Millions</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Purchase price:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Cash</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">885</td> <td valign="bottom">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Identifiable net assets:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Cash</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Marketable securities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td valign="bottom">  </td></tr> <tr><td valign="top"> Inventory(1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Other current and long-term assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29</td> <td valign="bottom">  </td></tr> <tr><td valign="top"> In-process research and development(2) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">448</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Intangible assets – Technology(3) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">230</td> <td valign="bottom">  </td></tr> <tr><td valign="top"> Deferred income taxes</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Other current and long-term liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(91</td> <td valign="bottom">) </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td> </td></tr> <tr><td valign="top"> Total identifiable net assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">870</td> <td valign="bottom">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td> </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Goodwill</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15</td> <td valign="bottom">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 3px double;" valign="bottom"> </td> <td style="border-top: #000000 3px double;" valign="bottom"> </td> <td> </td></tr></table>   <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(1)</td> <td class="MetaData" valign="top" align="left">Includes $63 million recorded in other long term assets as inventory that is expected to be utilized in excess of one year. </td></tr></table> <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(2)</td> <td class="MetaData" valign="top" align="left">Includes $310 million related to pegylated-interferon lambda. </td></tr></table> <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(3)</td> <td class="MetaData" valign="top" align="left">Attributed to RECOTHROM which is amortized over 10 years. </td></tr></table></div> </div>                Dollars in Millions   PurchasefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringPurchase Price Allocation [Text Block]No authoritative reference available.falsefalsePurchase Price Allocation4false0bmy_AdjustedPurchasePriceAllocationTextBlockbmyfalsenadurationAdj usted Purchase Price Allocation [Text Block]falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00<div> <div class="MetaData"> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="87%"> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Dollars in Millions</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Purchase price:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Cash</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,285</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Fair value of the Company's equity in Medarex held prior to acquisition(1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46</td> <td valign="bottom">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td> </td></tr> <tr><td valign="top"> Total</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,331</td> <td valign="bottom">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td> </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Identifiable net assets:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Cash</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Marketable securities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">269</td> <td valign="bottom">  </td></tr> <tr><td valign="top"> Other current and long-term assets(2) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> In-process research and development(3) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,475</td> <td valign="bottom">  </td></tr> <tr><td valign="top"> Intangible assets - Technology(4) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">120</td> <td valign="bottom">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Intangible assets - Licenses(5) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">315</td> <td valign="bottom">  </td></tr> <tr><td valign="top"> Short-term borrowings</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(92</td> <td valign="bottom">) </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Other current and long-term liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(92</td> <td valign="bottom">) </td></tr> <tr><td valign="top"> Deferred income taxes</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(352</td> <td valign="bottom">) </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Total identifiable net assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,823</td> <td valign="bottom">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td style="border-top: #000000 1px solid;" valign="bottom"> </td> <td> </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top"> Goodwill</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">508</td> <td valign="bottom">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-top: #000000 3px double;" valign="bottom"> </td> <td style="border-top: #000000 3px double;" valign="bottom"> </td> <td> </td></tr></table>   <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(1)</td> <td class="MetaData" valign="top" align="left">Other income of approximately $21 million was recognized from the remeasurement to fair value of the equity interest in Medarex held at the acquisition date. </td></tr></table> <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(2)</td> <td class="MetaData" valign="top" align="left">Includes a 5.1% ownership interest in Genmab ($64 million) and an 18.7% ownership in Celldex Therapeutics, Inc. ($17 million), which have been subsequently sold as of December 31, 2009 for a loss of $33 million. </td></tr></table> <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(3)</td> <td class="MetaData" valign="top" align="left">Includes approximately $1.0 billion related to YERVOY. </td></tr></table> <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(4)</td> <td class="MetaData" valign="top" align="left">Amortized over 10 years. </td></tr></table> <table style="border-collapse: collapse;" class="MetaData" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr><td valign="top" width="3%" align="left">(5)</td> <td class="MetaData" valign="top" align="left">Amortized over 13 years. </td></tr></table></div> </div>                Dollars in Millions   PurchasefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringAdjusted Purchase Price Allocation [Text Block]No authoritative reference available.falsefalseAdjusted Purchase Price Allocation13ACQUISITIONS (Tables)UnKnownUnKnownUnKnownUnKnownfalsetrue